NEW YORK--(BUSINESS WIRE)--ZIOPHARM Oncology, Inc. (Nasdaq: ZIOP) announced today that it will present data for all three of the Company’s clinical-stage product candidates -- darinaparsin (ZinaparTM or ZIO-101), palifosfamide (ZymafosTM or ZIO-201) and indibulin (ZybulinTM or ZIO-301) -- at the 45th Annual Meeting of the American Society of Clinical Oncology (ASCO) held in Orlando, FL, from May 29th to June 2nd.
